

2010 ATLANTA EMA RYAN WHITE PART A CLINICAL PERFORMANCE

Quality Management Committee Meeting
Metropolitan Atlanta HIV Health Services Planning Council

March 3, 2011

Rebecca J. Culyba, PhD

Center for Applied Research and Evaluation Studies
Southeast AIDS Training and Education Center
Department of Family and Preventive Medicine
Emory University School of Medicine



Purpose

- To monitor the quality of care provided by Ryan White Part A funded primary care sites as part of the Atlanta Eligible Metropolitan Area's quality management plan



Improvements

- Sampling methodology
- HAB HIV/AIDS Core Clinical Performance Measures for Adults and Adolescents
 - Groups 1-3
- Revisions to EMA indicators
- Data collection on laptops



Data limitations

- Electronic medical records
- Cannot compare to previous years
 - Different selection criteria
 - New sampling method
 - Revisions to some measures



Data considerations

- Intended to provide information on the clinic's documentation of ***current primary care practices*** for a representative sample of clients
- **NOT** intended to capture the historical clinic-patient relationship
- Services may be provided off-site and/or documented at a separate location
- For some indicators review goes back to the time of initial HIV diagnosis

Methods

- 8 Part A funded sites
- HIVQual sampling methodology
 - 739 charts reviewed
- Study period: CY 2009
- Selection criteria
 - Is at least 18 years old
 - Is currently living
 - Has had at least one medical visit in the study period
 - Has been seen in the last six months
 - Entire chart (if multiple volumes) is accessible



Key quality findings

- 40 % received an Oral Exam
- 95 % received 2 or more medical visits
 - *Measure of retention in care*
- 100% screened for Hepatitis C
- 93% Had HIV risk counseling
- 95% of new patients screened for mental health
- 97% of new patients screened for substance abuse
- Continued CAREWare data quality improvement

HRSA Group 1

Indicator	Data collection sites								
	All	1	2	3	4	5	6	7	8
ARV Therapy for Pregnant Women*	58	n/a	n/a	0	100	100	n/a	80	n/a
CD4 T-Cell Count*	89	88	92	96	88	94	90	68	98
HAART*	86	82	86	88	85	95	67	94	83
Medical Visits*	95	96	95	94	92	96	93	96	99
PCP Prophylaxis*	92	100	75	100	96	100	67	88	33

*Also Atlanta EMA performance measures.

HRSA Group 2

Indicator	Data collection sites								
	All	1	2	3	4	5	6	7	8
Adherence Assessment & Counseling*	88	88	92	90	93	96	71	98	73
Cervical Cancer Screening*†	--	--	--	--	--	--	--	--	--
Hepatitis B Vaccination	80	89	96	71	72	83	86	47	92
Hepatitis C Screening*	100	100	100	100	100	100	100	99	99
HIV Risk Counseling	93	74	97	98	99	97	90	98	94
Lipid Screening	84	76	78	100	81	60	99	93	95
Oral Exam	40	50	28	9	57	27	19	57	63
Syphilis Screening*	81	84	98	98	86	92	69	49	80
TB Screening*	97	100	96	89	97	100	95	98	100

*Also Atlanta EMA performance measures. † Investigating data anomaly. Resolution by time of final report.

HRSA Group 3

Indicator	Data collection sites								
	All	1	2	3	4	5	6	7	8
Chlamydia Screening	68	90	79	71	91	80	78	14	59
Gonorrhea Screening	69	90	79	71	91	80	79	14	59
Hepatitis B Screening	99	100	100	98	98	100	99	97	100
Hepatitis/HIV Alcohol Counseling	47	52	47	25	75	23	25	17	54
Influenza Vaccination	63	74	83	9	81	50	59	52	68

HRSA Group 3, cont.

Indicator	Data collection sites								
	All	1	2	3	4	5	6	7	8
MAC Prophylaxis	77	56	100	100	100	100	n/a	100	n/a
Mental Health Screening	95	100	100	86	89	88	96	100	100
Pneumococcal Vaccination	84	95	99	33	93	91	94	61	86
Substance Use Screening	97	100	100	100	94	88	96	100	100
Tobacco Cessation Counseling	57	52	51	67	75	61	68	18	43
Toxoplasma Screening	80	100	39	5	88	89	94	92	97

Atlanta EMA

Indicator	Data collection sites								
	All	1	2	3	4	5	6	7	8
Problem List	98	100	100	77	99	100	100	100	99
Allergies	100	100	100	100	99	99	100	100	99
Viral Load	11	10	13	20	4	15	10	6	15
Chlamydia Baseline Screening	32	36	60	25	18	6	41	4	68
Gonorrhea Baseline Screening	32	36	61	21	17	6	43	4	68
Nutrition Screening	68	88	44	48	87	66	70	38	95
Confirmatory Test	78	56	84	95	43	97	86	81	97

Where should QM efforts focus?

- Cervical cancer screening
- CAREWare – select measures
 - Group 1: CD4, HAART, PCP prophylaxis
- Reconsider select EMA-only indicators
 - Baseline Chlamydia and Gonorrhea
 - Viral Load Tests
 - Western Blot
- HRSA System-level performance measures
 - Focus on linkage to care
 - Access, HIV test results, disease status at entry



Next steps

- Additional chart abstractions in 2011
 - Adolescents
 - OB clinic
- HRSA System-level performance measures
 - Focus on linkage to care
 - Access, HIV test results, disease status at entry



Acknowledgements

- Ryan White Part A funded primary care sites
- Metropolitan Atlanta HIV Health Services Planning Council's Quality Management Committee
- Study team:
 - Sridevi Wilmore MPH
 - Tiffany Burgess MPH
 - Susan Richardson MN, MPH, CFNP
 - Barbara Blake RN, PhD, ACRN
 - Gloria Taylor DSN, RN